Quick Preview
✔️ Cerebral Vascular Accident — Visual Field Loss & Suppression
68F
Post-stroke (CVA, left parietal)
Hemianopsia and left-eye suppression
Regained fusion after coMra + syntonics
Stroke with Headaches and Loss of Visual Field
(Click to Expand)
Quick Facts
- Patient: 68-year-old female
- Condition: Headaches and loss of visual field following stroke in the right side of the brain
- Context: Stroke caused a large blind spot affecting the left visual field of both eyes; nerve pathway involvement impacted both eyes seeing to the left.
- Protocol: Treatment started 5 months after stroke onset. 12 treatments done over 3 months. coMra Delta 905 used. Eye Protocol (point 2 only, modified, 5 minutes per side) + 50 Hz (5 minutes at stroke site). 6 syntonics treatments also done.
- Outcome Highlights:
- Visual field completely restored (confirmed by visual field testing at the end of the treatment program)
- Headaches much less frequent and much less intense
📂 Expand Full Case Details
#### **Case Details**Medical History:
Early glaucoma, high blood pressure, diabetes, heart disease
Medications at Start:
Pravastin, Sotalol, Fenofiery, Oneprazo, Coumadin, Metfromin, Travatan Z, Aspirin, Calcium
Practitioner Notes:
- Visual field loss fully restored, confirmed by visual field testing at the end of the treatment program
- Patient reported headaches were much less frequent and much less intense
- Overall improvement rated as Substantially Improved (65–89% better)
Patient Comment:
“She is very happy!”
Follow-up:
Awaiting patient return for post-treatment check-up report
Related science:
- Transcranial low-intensity laser + magnetic therapy improved visual fields, VEP, and ocular blood flow in POAG patients (n=165 eyes, Egorov 2013; n≈400 eyes across cohorts, Kamenskikh 2012), supporting plausibility for post-stroke field recovery.
- In POAG with cerebral ischemia, transcranial magnetic/laser regimens improved fields, VEP latency, and hemodynamics (n≈400 eyes, Kamenskikh 2012). Similarly, in vascular and ischemic optic-nerve subgroups, multi-modal low-intensity therapy showed durable gains (n=88 eyes, Baranov 2016), suggesting mechanisms that may also underlie reduced headache burden.
✅ Next Steps for Clinicians
📂 Expand For Details
📅 Book a Call
Explore how coMra could fit into your care model Schedule a Conversation →
📄 Download Clinical Brief
Access protocols and objective outcomes
Get the Brief →
💬 Ask a Clinical Question
Get direct answers from our clinical team
Submit Your Question →📨
👉 Return to Eye Main Page